Hubbry Logo
IdebenoneIdebenoneMain
Open search
Idebenone
Community hub
Idebenone
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Idebenone
Idebenone
Idebenone
View on Wikipedia
from Wikipedia

Idebenone
Clinical data
Trade namesCatena, Raxone, Sovrima
AHFS/Drugs.comInternational Drug Names
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • EU: Rx-only[1]
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability<1% (high first pass effect)
Protein binding>99%
Elimination half-life18 hours
ExcretionUrine (80%) and feces
Identifiers
  • 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-
    cyclohexa-2,5-diene-1,4-dione
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H30O5
Molar mass338.444 g·mol−1
3D model (JSmol)
  • O=C1/C(=C(\C(=O)C(\OC)=C1\OC)C)CCCCCCCCCCO
  • InChI=1S/C19H30O5/c1-14-15(12-10-8-6-4-5-7-9-11-13-20)17(22)19(24-3)18(23-2)16(14)21/h20H,4-13H2,1-3H3 checkY
  • Key:JGPMMRGNQUBGND-UHFFFAOYSA-N checkY
  (verify)

Idebenone, sold under the brand name Raxone among others, is a medication that was initially developed by Takeda Pharmaceutical Company for the treatment of Alzheimer's disease and other cognitive defects.[2] This has been met with limited success. The Swiss company Santhera Pharmaceuticals has started to investigate it for the treatment of neuromuscular diseases. In 2010, early clinical trials for the treatment of Friedreich's ataxia[3] and Duchenne muscular dystrophy[4] have been completed. As of December 2013 the drug is not approved for these indications in North America or Europe. It is approved by the European Medicines Agency (EMA) for use in Leber's hereditary optic neuropathy (LHON) and was designated an orphan drug in 2007.[5]

Chemically, idebenone is an organic compound of the quinone family. It is also promoted commercially as a synthetic analog of coenzyme Q10 (CoQ10).

Uses

[edit]

Indications that are or were approved in some territories

[edit]

Nootropic effects and Alzheimer's disease

[edit]

Idebenone improved learning and memory in experiments with mice.[6] In humans, evaluation of Surrogate endpoints like electroretinography, auditory evoked potentials and visual analogue scales also suggested positive nootropic effects,[7] but larger studies with hard endpoints are missing.

Research on idebenone as a potential therapy of Alzheimer's disease have been inconsistent, but there may be a trend for a slight benefit.[8][9] In May 1998, the approval for this indication was cancelled in Japan due to the lack of proven effects. In some European countries, the drug is available for the treatment of individual patients in special cases.[2]

Friedreich's ataxia (Sovrima)

[edit]

Preliminary testing has been done in humans and found idebenone to be a safe treatment for Friedreich's ataxia (FA), exhibiting a positive effect on cardiac hypertrophy and neurological function.[10] The latter was only significantly improved in young patients.[11] In a different experiment, a one-year test on eight patients, idebenone reduced the rate of deterioration of cardiac function, but without halting the progression of ataxia.[12]

The drug was approved for Friedreich's ataxia in Canada in 2008 under conditions including proof of efficacy in further clinical trials.[13] However, in February 2013, Health Canada announced that idebenone would be voluntarily recalled as of April 2013 by its Canadian manufacturer, Santhera Pharmaceuticals, due to the failure of the drug to show efficacy in the further clinical trials that were conducted.[14] In 2008, the European Medicines Agency (EMA) refused a marketing authorisation for this indication.[2] As of 2013 the drug was not approved for FA in Europe[15] nor in the US, where, as of February 2023, there is only one approved treatment.[16]

Leber's hereditary optic neuropathy (Raxone)

[edit]

Leber's hereditary optic neuropathy (LHON) is a mitochondrially inherited (mother to all offspring) degeneration of retinal ganglion cells (RGCs) and their axons that leads to an acute or subacute loss of central vision; this affects predominantly young adult males. Santhera completed a Phase III clinical trial in this indication in Europe with positive results,[17] and submitted an application to market the drug to European regulators in July 2011.[18] It is approved by EMA for this indication and was designated an orphan drug in 2007.[5]

Indications being explored

[edit]

Duchenne muscular dystrophy (Catena)

[edit]

After experiments in mice[19] and preliminary studies in humans, idebenone has entered Phase II clinical trials in 2005[4] and Phase III trials in 2009.[20]

Other neuromuscular diseases

[edit]

Phase I and II clinical trial for the treatment of MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) was conducted.[21] Phase I/II trial for primary progressive multiple sclerosis concluded that Idebenone did not inhibit disability progression.[22][23]

As of 2022, a phase III clinical trial is ongoing for the treatment of Parkinson's disease.[24]

Life style

[edit]

Idebenone is claimed to have properties similar to CoQ10 in its antioxidant properties, and has therefore been used in anti-aging on the basis of free-radical theory. Clinical evidence for this use is missing. It has been used in topical applications to treat wrinkles.[25]

Pharmacology

[edit]

In cellular and tissue models, idebenone acts as a transporter in the electron transport chain of mitochondria and thus increases the production of adenosine triphosphate (ATP) which is the main energy source for cells, and also inhibits lipoperoxide formation. Positive effects on the energy household of mitochondria has also been observed in animal models.[2][26] Clinical relevance of these findings has not been established.

Pharmacokinetics

[edit]

Idebenone is well absorbed from the gut but undergoes excessive first pass metabolism in the liver, so that less than 1% reach the circulation. This rate can be improved with special formulations (suspensions) of idebenone and by administering it together with fat food; but even taking these measures bioavailability still seems to be considerably less than 14% in humans. More than 99% of the circulating drug are bound to plasma proteins. Idebenone metabolites include glucuronides and sulfates, which are mainly (~80%) excreted via the urine.[2]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Idebenone

View on Grokipedia
from Grokipedia
Idebenone is a synthetic derivative and analog of (CoQ10), featuring a shorter idebenyl that enhances its water solubility and ability to cross biological membranes compared to the natural compound. Developed in the 1980s by Takeda Pharmaceuticals in as a agent, idebenone primarily functions as a mitochondrial carrier, shuttling electrons directly to complex III of the respiratory chain to bypass defects in complex I, thereby supporting ATP production and mitigating . It also exhibits potent properties by scavenging (ROS) and inhibiting , which helps protect cells from mitochondrial dysfunction and . Clinically, idebenone is most notably used to treat mitochondrial disorders, particularly (LHON), a rare genetic condition causing acute vision loss due to complex I deficiency. Approved by the (EMA) in 2015 under the brand name Raxone for LHON in adolescents and adults, it is administered orally at doses up to 900 mg daily and has demonstrated efficacy in preserving or improving in clinical trials, such as the 2024 LEROS study. As of November 2025, the U.S. (FDA) has granted priority review for idebenone's for LHON, with a target decision date of February 28, 2026, potentially marking its first approval in the United States if successful. It has also shown benefits in other neurological conditions, including —where a 2007 phase II trial reported improved neurological function with high-dose therapy—and , with a 2015 phase III study indicating enhanced respiratory function. Beyond , idebenone's therapeutic potential extends to non-mitochondrial applications, such as reducing oxidative damage in cardiovascular diseases, diabetes-related complications, and certain cancers, though these remain investigational and supported primarily by preclinical or early-phase studies as of 2025. Additionally, its profile has led to topical formulations for dermatological uses, including anti-aging and protection against UV-induced skin damage, leveraging its stability and low irritation potential. Ongoing research emphasizes optimizing its delivery to improve , given its rapid and limited systemic exposure after .

Medical uses

Approved indications

Idebenone received initial regulatory approval in in 1986 for the treatment of cognitive and behavioral disorders associated with and other forms of senile , where it was marketed under the brand name Avan by Takeda Chemical Industries. This approval was based on its properties, demonstrated in preclinical studies showing improvements in learning and memory retention in animal models of . Clinical evaluations in Japanese patients supported its use for enhancing memory and cognitive function, though the approval was withdrawn in 1998 due to insufficient evidence of long-term efficacy in post-marketing re-evaluations. In , idebenone was granted conditional market approval in July 2008 under the brand name Catena for the treatment of , marking the first regulatory endorsement for this mitochondrial disorder. The approval was based on early clinical data suggesting potential cardiac benefits, with recommended dosing starting at 5 mg/kg/day (up to a maximum of 1,350 mg/day in divided doses), and required the sponsor to conduct confirmatory Phase III trials to verify efficacy. However, following the negative results of the Phase III trial, which showed no significant improvement in neurological function or cardiac hypertrophy after 6 months of treatment at doses up to 2,250 mg/day compared to , the marketing authorization was voluntarily withdrawn in April 2013. Idebenone is approved in the as Raxone for the treatment of in adolescent and adult patients (aged 12 years and over) with (LHON), with marketing authorization granted by the on September 8, 2015. This approval was supported by the pivotal Phase III trial, a randomized, -controlled study of 85 patients receiving 900 mg/day (300 mg three times daily with food) for 24 weeks, which demonstrated a trend toward better recovery; in the intent-to-treat , 37.7% of idebenone-treated patients achieved a clinically meaningful improvement of 15 or more letters on the ETDRS compared to 24.1% on . In August 2025, the UK's National Institute for Health and Care Excellence (NICE) recommended Raxone for routine NHS use in eligible LHON patients, facilitating access starting in late 2025 through a managed access agreement. In the United States, the FDA accepted a for idebenone in LHON under in September 2025, with a target action date of February 28, 2026; if approved, it would represent the first FDA-endorsed therapy for this rare . Long-term data from the Phase IV study and RHODOS observational follow-up, involving over 200 LHON patients treated with 900 mg/day for up to 24 months, confirm sustained benefits, with significantly higher rates of clinically relevant recovery (defined as 10-letter or greater improvement) at 12 and 24 months compared to untreated historical controls. As a synthetic analog of , idebenone supports mitochondrial electron transport in LHON-affected retinal ganglion cells, contributing to these neuroprotective effects in the acute and subacute phases of vision loss.

Investigational and off-label uses

Idebenone has been explored in (DMD) under the brand Catena to address respiratory decline driven by mitochondrial dysfunction in . The phase 3 DELOS trial (NCT01027884), published in 2015, involved 64 steroid-naïve patients aged 10-18 years and showed that idebenone at 900 mg/day reduced the decline in as a percentage of predicted value by 66% compared to over 52 weeks (adjusted mean difference 6.27 percentage points, p=0.031). However, a subsequent phase 3 trial (SIDEROS, NCT02814019) in glucocorticoid-treated patients failed to replicate these benefits on respiratory function, contributing to mixed outcomes across phase 3 studies and no regulatory approval for DMD, with development discontinued in 2020. Small-scale studies have investigated idebenone in other neuromuscular diseases involving mitochondrial dysfunction, such as mitochondrial encephalomyopathies (e.g., ) and , aiming to enhance motor function through improved energy metabolism. A phase 2 trial in (NCT00887562) with 21 patients assessed idebenone's impact on cerebral lactate levels and neurological symptoms but found no significant changes, limited by its small sample size of under 30 participants. In primary progressive , an exploratory phase 2 trial (NCT01854359) with 44 patients over 24 months reported no inhibition of disability progression on the , despite confirming safety, underscoring the need for larger validation studies. Case reports, such as long-term idebenone combined with in , have noted prevention of stroke-like episodes and modest motor stability in individual patients, but these lack controlled, large-scale confirmation. Off-label applications include post-stroke , where idebenone's effects support ATP production to counteract ischemic mitochondrial damage and alleviate deficits. A 2025 real-world study of 120 patients demonstrated that 90 days of idebenone (450-900 mg/day) significantly improved scores by 4.2 points versus baseline (p<0.001), with reductions in oxidative stress markers and enhanced neurological recovery, though as an observational design, it highlights the need for randomized trials. Emerging preclinical research as of 2025 targets non-neurological conditions tied to mitochondrial dysfunction, such as cardiovascular diseases, diabetes, and liver diseases, with idebenone disrupting pathological processes via electron shuttling and ROS modulation. In cardiovascular models, idebenone attenuated ferroptosis in myocardial infarction mouse models through ROS-AMPK-mTOR signaling, preserving cardiac function. For diabetes, it improved insulin sensitivity and glycemic control in high-fat diet mouse models by inhibiting Shc protein and activating GLP-1 receptors. In liver diseases, idebenone reduced ethanol-induced hepatotoxicity in mice via NLRP3 inflammasome suppression, limiting oxidative damage. Preclinical data also indicate cancer cell disruption through mitochondrial targeting, including apoptosis induction in triple-negative breast cancer xenografts via AMPK/mTOR inhibition and proliferation suppression in hepatocellular carcinoma via ROS regulation in HepG2 cells. These findings build on idebenone's rationale for mitochondrial disorders, akin to its benefits in , but are constrained by small preclinical cohorts and absence of clinical translation.

Adverse effects and contraindications

Adverse effects

Idebenone is generally well tolerated, with most adverse effects being mild to moderate and primarily involving the gastrointestinal system. Common effects include diarrhea (mild to moderate); nausea, abdominal pain, and vomiting have been reported but with frequency not estimable from available data. These gastrointestinal symptoms are often dose-dependent, though overall tolerability remains acceptable up to 900 mg/day. Less common adverse effects encompass headache, dizziness, nasopharyngitis, cough, and back pain. Elevations in liver enzymes, such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST), have been observed rarely, prompting recommendations for periodic monitoring during therapy. In key clinical trials, including the RHODOS study for Leber's hereditary optic neuropathy (LHON) at 900 mg/day and the DELOS trial for DMD at 900 mg/day, the incidence of these effects was comparable to placebo, with no increase in serious adverse events. In trials like DELOS, the incidence of serious adverse events was lower in idebenone-treated patients compared to placebo. Rare serious effects include hypersensitivity reactions, such as rash and pruritus, reported in post-marketing surveillance for Raxone (idebenone) primarily in LHON patients. Long-term studies, including up to 2 years of treatment at 300 mg/day in elderly patients with cognitive disorders, have shown no remarkable safety issues beyond transient gastrointestinal upset, supporting the drug's favorable profile with prolonged use. In the IONIA trial for Friedreich's ataxia at 1350-2250 mg/day, adverse events were similar to placebo, with gastrointestinal intolerance being the primary concern at higher doses but rarely leading to discontinuation. As of June 2025 (EMA renewal), the safety profile remains consistent with no new signals.

Contraindications and precautions

Idebenone is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients, such as lactose or sunset yellow FCF, in formulations like Raxone. Precautions are necessary in patients with hepatic impairment, as idebenone is metabolized primarily via oxidative processes involving liver enzymes including , , , and ; no specific dose adjustments are required, but caution and regular monitoring for adverse events are advised, potentially leading to treatment interruption if needed. Idebenone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, as its safety in pregnant women has not been established, although animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity, embryonic/foetal development, parturition, or post-natal development. In lactating women, idebenone and/or its metabolites are excreted in human milk, so a decision must be made whether to discontinue breastfeeding or the treatment, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman. For pediatric use, the safety and efficacy of idebenone have not been established in children under 12 years of age, with no data available, though it is approved for visual impairment associated with Leber's hereditary optic neuropathy (LHON) in adolescents aged 12 years and older, and treatment in younger children should be considered on a case-by-case basis given the potentially less severe disease course. Regarding drug interactions, idebenone is a mild inhibitor of and may inhibit , potentially affecting the exposure of sensitive substrates such as cyclosporine, tacrolimus, or digoxin, though data from clinical studies indicate no clinically significant interactions after multiple dosing, and its short half-life contributes to minimal overall impact on clearance; no major interactions were reported in LHON trials. In elderly patients, no dose adjustment is required, as there is no evidence of altered pharmacokinetics necessitating changes, though caution is advised in those with gastrointestinal compromise due to potential for common effects like diarrhea.

Pharmacology

Pharmacodynamics

Idebenone is a synthetic, short-chain analog of coenzyme Q10 (ubiquinone), featuring a shortened hydroxydecyl side chain consisting of 10 carbons with a terminal hydroxyl group, which enhances its polarity, solubility, and ability to penetrate cell and mitochondrial membranes compared to the longer-chain ubiquinone. This structural modification allows idebenone to more readily enter cells and interact with mitochondrial components, supporting its role in addressing mitochondrial dysfunction. As an electron carrier, idebenone facilitates electron transfer within the mitochondrial respiratory chain by bypassing defects in complex I, thereby restoring ATP production and mitigating oxidative stress in impaired mitochondria. The reduced form of idebenone, idebenol, donates electrons directly to complex III, sustaining coupled respiration and ATP synthesis even in the presence of complex I inhibitors like . Idebenone exhibits potent antioxidant properties by scavenging reactive oxygen species (ROS) and protecting against lipid peroxidation, particularly in the context of mitochondrial diseases. It regenerates other antioxidants, such as vitamin E, through electron transfer mechanisms that bolster cellular defense against oxidative damage. In Leber's hereditary optic neuropathy (LHON), idebenone enhances NADH dehydrogenase (complex I) activity in patient-derived fibroblasts, increasing enzymatic function by approximately 42% without altering respiration in healthy control cells. For Friedreich's ataxia, idebenone supports frataxin-deficient cells by acting as a free radical scavenger that reduces mitochondrial oxidative stress and iron-sulfur protein deficiencies associated with frataxin mutations. Idebenone demonstrates selectivity for dysfunctional mitochondria, exerting minimal effects on healthy ones, as evidenced by its lack of impact on respiratory parameters or complex I activity in normal fibroblasts. In animal models of neuroprotection, idebenone exhibits a dose-response relationship, proving effective at doses around 30 mg/kg to alleviate oxidative damage and support mitochondrial function.

Pharmacokinetics

Idebenone is rapidly absorbed after oral administration, with peak plasma concentrations (Cmax) typically reached within 1 hour (median Tmax of 0.67 hours, range 0.33–2.00 hours) following repeat dosing. The bioavailability is significantly enhanced when taken with food, increasing by approximately 5- to 7-fold compared to conditions, due to improved absorption and reduced first-pass . Pharmacokinetic studies in healthy volunteers have shown dose-proportional increases in Cmax and area under the curve (AUC) for doses ranging from 150 mg to 1,050 mg, with linear kinetics maintained up to 2,250 mg daily without significant accumulation upon multiple dosing. As a highly lipophilic compound, idebenone distributes widely and efficiently crosses the blood-brain barrier, achieving detectable concentrations in cerebral tissue and the aqueous humor of the eye, which supports its effects. It exhibits high (>98.5%). Idebenone undergoes extensive hepatic metabolism primarily through oxidative shortening of its side chain by enzymes, including , , , , and , followed by conjugation via and sulfation to form inactive metabolites such as QS10, QS8, QS6, QS4, and their conjugates (e.g., idebenone-C, QS4-C). Over 99% of the parent drug is metabolized, with no active metabolites contributing to pharmacological activity, and the main circulating species in plasma are the conjugated forms like QS4 and QS4-C. Elimination occurs mainly via , with a terminal of the parent ranging from approximately 3 to 15 hours depending on dose and regimen (e.g., 3.1 hours for a single 150 mg dose, up to 15 hours for repeated 750 mg doses). Metabolites are primarily excreted renally, with 56–78% of the dose recovered in urine (mostly as QS4 conjugates, <1% unchanged ), and the remainder via feces following biliary ; total clearance reflects high first-pass extraction. In human studies, including (LHON) trials such as (900 mg/day), steady-state plasma levels were consistent with single-dose , showing proportional exposure without accumulation after 24 weeks of dosing.

Non-medical uses

Cosmetic applications

Idebenone is employed topically in skincare formulations, such as creams and serums, at concentrations typically ranging from 0.5% to 1.0%, to serve as a potent that addresses and damage from environmental stressors like UV radiation. These products aim to mitigate signs of aging by protecting cellular structures from oxidative damage. In the skin, idebenone functions by neutralizing free radicals generated by UV exposure, thereby reducing without causing irritation. Its efficacy stems from a superior ability to scavenge free radicals, outperforming vitamins C and E in overall protection capacity. This structural similarity to enhances its properties while allowing better lipid solubility for dermal absorption. Clinical evidence supports these benefits, with a six-week randomized involving women with moderate photodamaged demonstrating significant improvements using 1.0% idebenone applied twice daily: a 26% reduction in skin roughness and dryness, a 37% increase in hydration, and a 29% decrease in fine lines and wrinkles. Similar though slightly lesser effects were observed at 0.5% concentration, alongside histological reductions in inflammatory markers and increases in production. Commercially, idebenone features prominently in anti-aging serums from brands like Elizabeth Arden's Prevage line, which targets wrinkle reduction and firmness, and Mary & May's Idebenone + Blackberry Complex Serum, emphasizing elasticity and glow enhancement through synergistic antioxidants. Topically, idebenone is well-tolerated across types, with clinical studies reporting no significant adverse effects or induction of , making it suitable for daily use in sun-exposed areas. In 2025, its incorporation into K-beauty antioxidant complexes has driven market growth, with the global idebenone skincare sector projected to expand from $1.25 billion in 2024 to $3.47 billion by 2033. Despite these applications, idebenone's skincare uses rely on cosmetic claims rather than FDA regulation as a , limiting assertions to aesthetic improvements without therapeutic guarantees.

Dietary supplements

Idebenone is marketed as a nutritional supplement primarily for supporting production and providing protection, often formulated in capsules ranging from 45 mg to 300 mg for daily wellness use. These products are promoted to enhance cellular through mitochondrial function, leveraging idebenone's structural similarity to (CoQ10) while offering potentially superior due to its shorter, more hydrophilic side chain, which facilitates better tissue penetration, particularly in the . Supplement manufacturers commonly claim benefits for mitochondrial health in contexts such as aging or fatigue, attributing these to idebenone's ability to bypass certain mitochondrial electron transport chain defects and support ATP production, akin to CoQ10 but with enhanced solubility and uptake. However, evidence for these general wellness applications remains limited; small-scale studies in elderly populations have reported improvements in cognitive function and implied enhancements in cerebral metabolism, such as through better scores on standardized tests like the Sandoz Clinical Assessment-Geriatric scale following 90 mg daily dosing over several months. No large randomized controlled trials (RCTs) substantiate broad supplementation efficacy for non-clinical energy or fatigue support, with most data derived from disease-specific investigations rather than healthy or mildly symptomatic individuals. In the United States and , idebenone supplements are widely available over-the-counter through online retailers and health food stores as non-prescription products, exempt from FDA pre-market approval for efficacy under the Health and Education Act, though they must adhere to good manufacturing practices for safety. Recommended dosages for supplemental use typically range from 45-90 mg per day, substantially lower than the 300-900 mg daily employed in clinical settings, reflecting a focus on preventive wellness rather than therapeutic intervention. This accessibility raises concerns about for mitochondrial-related concerns, where users may exceed suggested doses without medical oversight. By 2025, idebenone has gained traction in anti-aging protocols, often stacked with CoQ10 in formulations targeting and vitality, driven by consumer interest in mitochondrial-targeted nutraceuticals.

History

Development and early research

Idebenone was developed by in the early 1980s as a synthetic analog of (CoQ10) to enhance brain metabolism and treat cognitive decline associated with . The synthesis involved shortening the polyisoprenoid tail of ubiquinone, the oxidized form of CoQ10, to increase and facilitate better tissue uptake compared to the longer-tailed natural compound. This structural modification was part of Takeda's efforts to create a more bioavailable derivative for neurological applications. Early preclinical research in the centered on animal models of cerebral ischemia, where idebenone exhibited neuroprotective effects. In rat studies, it improved local cerebral blood flow, preserved energy metabolism, and reduced neurological deficits following experimental ischemia, suggesting potential benefits for conditions involving and mitochondrial impairment. These findings, including restoration of succinate oxidation in CoQ10-depleted mitochondria from rats and canines, supported its advancement to human testing as a cerebroactive agent. The first human trials occurred in in the mid-1980s, evaluating idebenone's safety and efficacy in patients with cognitive disorders. These efforts culminated in its approval by Japanese regulatory authorities in 1986 for treating and emotional disturbances linked to cerebrovascular issues, marking the initial clinical milestone. Pre-2000s primarily explored idebenone's effects in through small-scale trials involving 100-200 participants. Multicenter studies reported modest cognitive enhancements, such as improved memory and daily functioning scores, though outcomes varied and lacked consistent across larger cohorts. By the late 1990s, investigations shifted toward mitochondrial disorders following the identification of gene mutations in , highlighting idebenone's potential to bypass defective electron transport and alleviate related bioenergetic deficits in preclinical models.

Regulatory milestones

Idebenone received approval in in 1986 from the Ministry of Health and Welfare for treating and emotional disturbances linked to cerebrovascular issues. The was marketed under the brand name Avance until May 1998, when the approval was revoked due to insufficient evidence of efficacy. In the , idebenone was granted designation for on 8 March 2004 (EU/3/04/189). It later received orphan designation for (LHON) on 15 February 2007 (EU/3/07/434). Following positive results from the Phase III trial, the approved Raxone (idebenone) on 8 September 2015, for the treatment of in adolescent and adult patients with LHON. Health Canada issued conditional market authorization for idebenone (marketed as Sovrima or Catena) on July 24, 2008, for the treatment of in patients aged 8 years and older. The authorization was withdrawn voluntarily by the manufacturer in April 2013 following the negative outcome of the Phase III trial, which failed to demonstrate efficacy. Idebenone has no prior approvals from the U.S. (FDA). In July 2016, the FDA denied Santhera Pharmaceuticals' request for accelerated approval of idebenone (Raxone) for , determining that the submitted data did not support the proposed surrogate endpoint. More recently, on September 22, 2025, the FDA accepted a from Chiesi Global Rare Diseases for idebenone in LHON and granted , setting a PDUFA target action date of February 28, 2026; the submission relies on data from an program. The National Institute for Health and Care Excellence (NICE) in the issued technology appraisal guidance TA1093 on August 28, 2025, recommending idebenone (Raxone) for treating associated with LHON in people aged 12 years and over, subject to a commercial access agreement; this enables reimbursement and access via the from late 2025. Ongoing pediatric investigations for idebenone, particularly in , include assessments of neurological efficacy and safety in children, building on prior controlled studies.

Society and culture

Brand names and formulations

Idebenone is commercially available primarily under branded formulations for medical use in treating (LHON) and historically for . The primary brand is Raxone, developed by Santhera Pharmaceuticals and now marketed and distributed by S.p.A., which is formulated as 150 mg film-coated tablets for oral administration. The recommended dosage for LHON is 900 mg per day, administered as 300 mg (two 150 mg tablets) three times daily with food to enhance absorption. In , idebenone was marketed as Catena by Santhera Pharmaceuticals in 150 mg film-coated tablet form, approved conditionally in 2008 for , but voluntarily withdrawn from the market in 2013. Access may be available through Health Canada's Special Access Programme. Historical formulations under the Sovrima brand, by Santhera, were 150 mg tablets intended for in , but the marketing authorisation application was refused by the EMA in 2008 due to insufficient evidence of efficacy. For trials, Sovrima and Catena were investigated at doses up to 900-2250 mg daily, but neither received sustained approval for this indication. In , idebenone was previously sold as Avan by in 30 mg and 90 mg tablet formulations for associated with cerebrovascular disorders, with typical dosing of 30-90 mg three times daily after meals; however, it was discontinued in 1998. Generic versions of idebenone remain limited globally, with availability restricted to branded products in the , the , , and select other markets. In the United States, no approved formulations exist as of November 2025, though Chiesi Global Rare Diseases submitted a for oral idebenone tablets (likely 150 mg) for LHON, accepted for priority review by the FDA in September 2025 with a target action date of February 28, 2026. All approved medical formulations of idebenone are immediate-release oral tablets or film-coated tablets, with no injectable, topical, or extended-release options authorized. In pediatric clinical trials for , idebenone has been administered at doses of 5 mg/kg per day, often using a powder-for-suspension to facilitate weight-based dosing in younger patients. Primary manufacturing remains with Santhera Pharmaceuticals for current brands, while Takeda's role is limited to the discontinued Avan product. In 2019, Santhera Pharmaceuticals licensed the rights to Raxone to Chiesi Group for commercialization in most territories outside and . Idebenone is approved as a medicinal product in the under the brand name Raxone for the treatment of visual impairment in adolescent and adult patients with (LHON), with marketing authorization granted by the on September 8, 2015. This approval extends to several non-EU countries, including the (2015), (2017), (2019), (2019), (2024), and (2024), where it is available by prescription for the same indication. In , idebenone was initially approved in 1986 for cognitive disorders associated with cerebral organic conditions but had its marketing authorization withdrawn in May 1998 due to insufficient evidence of efficacy. In the United States, idebenone has not received approval from the (FDA) as a drug or ingredient as of November 2025. It holds multiple designations for conditions such as LHON (2003), (2003), and mitochondrial disorders (2009), but no full approval has been granted. In September 2025, the FDA accepted a for idebenone (under the proposed brand name Raxone) for LHON treatment, granting it with a target action date of February 28, 2026; if approved, it would become the first therapy for this indication in the US. The FDA has explicitly stated that idebenone is an unapproved new drug and does not qualify as a ingredient under the Dietary Supplement Health and Education Act, as evidenced by a 2012 warning letter to a manufacturer for marketing it as such. Despite this, idebenone products are available over-the-counter in the US through some online retailers and supplement vendors, though their sale may violate FDA regulations. Outside of approved medicinal uses, idebenone's availability as a or cosmetic ingredient varies by jurisdiction and is generally unregulated or restricted. In regions without drug approval, such as and , it lacks formal regulatory status for therapeutic claims and is primarily accessible via import or specialty markets, often without endorsement for medical use.

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC12433227/
  2. https://www.ema.europa.eu/en/medicines/human/EPAR/raxone
  3. https://chiesirarediseases.com/media/20250922-idebenone-accepted-by-fda-for-priority-review-for-leber-hereditary-optic-neuropathy-lhon
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC5853719/
  5. https://link.springer.com/content/pdf/10.1007/s00415-009-1005-0.pdf
  6. https://newdrugapprovals.org/2021/01/11/idebenone/
  7. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/idebenone
  8. https://www.curefa.org/drug-development/idebenone-raxone-catena/
  9. https://pubmed.ncbi.nlm.nih.gov/11907009/
  10. https://pubmed.ncbi.nlm.nih.gov/21392622/
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC3170530/
  12. https://www.nice.org.uk/guidance/ta1093
  13. https://www.ophthalmologytimes.com/view/idebenone-accepted-by-fda-for-priority-review-for-leber-hereditary-optic-neuropathy
  14. https://www.neurology.org/doi/10.1212/WNL.0000000000205594
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC10982982/
  16. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60025-3/fulltext
  17. https://www.parentprojectmd.org/santhera-to-discontinue-phase-3-sideros-study-and-development-of-puldysa-in-duchenne/
  18. https://clinicaltrials.gov/study/NCT00887562
  19. https://pmc.ncbi.nlm.nih.gov/articles/PMC12580127/
  20. https://doi.org/10.1016/j.ejphar.2023.175569
  21. https://doi.org/10.1016/j.biopha.2024.117202
  22. https://doi.org/10.1002/jbt.22876
  23. https://doi.org/10.1080/01635581.2024.2314320
  24. https://www.ema.europa.eu/en/documents/product-information/raxone-epar-product-information_en.pdf
  25. https://pubmed.ncbi.nlm.nih.gov/21435876/
  26. https://jamanetwork.com/journals/jamaneurology/fullarticle/800798
  27. https://pubmed.ncbi.nlm.nih.gov/20955109/
  28. https://www.mdpi.com/2076-3921/10/2/236
  29. https://www.jneurosci.org/content/40/23/4609
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC3265671/
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC3285568/
  32. https://pubmed.ncbi.nlm.nih.gov/12069112/
  33. https://www.sciencedirect.com/science/article/abs/pii/016749438990006X
  34. https://pubmed.ncbi.nlm.nih.gov/19125241/
  35. https://www.tga.gov.au/sites/default/files/auspar-idebenone-200206.pdf
  36. https://files.core.ac.uk/download/pdf/159144834.pdf
  37. https://pubmed.ncbi.nlm.nih.gov/17129261/
  38. https://pubmed.ncbi.nlm.nih.gov/17134415/
  39. https://marynmay.us/products/mary-may-idebenone-blackberry-complex-serum-80ml
  40. https://researchintelo.com/report/idebenone-skincare-market
  41. https://www.webmd.com/vitamins/ai/ingredientmono-1078/idebenone
  42. https://www.supersmart.store/en/shop/brain-nutrition/idebenone-supplement-0259
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC7708875/
  44. https://www.sciencedirect.com/science/article/pii/S2213231715000105
  45. https://www.sciencedirect.com/science/article/pii/016749439290063A
  46. https://www.archivemarketresearch.com/reports/idebenone-366426
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC7913973/
  48. https://www.sciencedirect.com/science/article/abs/pii/S0891584919321860
  49. https://www.jstage.jst.go.jp/article/bpb1978/8/6/8_6_457/_article
  50. https://www.dovepress.com/idebenone-clinical-potential-beyond-neurological-diseases-peer-reviewed-fulltext-article-DDDT
  51. https://www.sciencedirect.com/science/article/pii/016749439290060H
  52. https://omim.org/entry/229300
  53. https://www.ema.europa.eu/en/documents/assessment-report/raxone-epar-public-assessment-report_en.pdf
  54. http://www.msdiscovery.org/research-resources/drug-pipeline/8692-idebenone
  55. https://www.biocentury.com/article/155506/catena-idebenone-regulatory-update
  56. https://www.mda.org/press-releases/fda-turns-down-santhera-pharmaceuticals%25E2%2580%2599-request-accelerated-approval-idebenone-treat
  57. https://pubmed.ncbi.nlm.nih.gov/21779958/
  58. https://www.swissmedic.ch/swissmedic/en/home/about-us/publications/public-summary-swiss-par/public-summary-swiss-par-raxone.html
  59. https://pdf.hres.ca/dpd_pm/00014074.PDF
  60. https://www.ema.europa.eu/en/medicines/human/EPAR/sovrima
  61. https://www.globenewswire.com/news-release/2025/09/22/3153874/0/en/Idebenone-Accepted-by-FDA-for-Priority-Review-for-Leber-Hereditary-Optic-Neuropathy-LHON.html
  62. https://www.santhera.com/assets/files/press-releases/2019-05-23_RaxLicense_e_final.pdf
  63. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=232006
  64. https://quackwatch.org/cases/fdawarning/prod/fda-warning-letters-about-products-2012/abco/
  65. https://www.drugs.com/history/idebenone.html
  66. https://go.drugbank.com/drugs/DB09081
Add your contribution
Related Hubs
User Avatar
No comments yet.